Description
PMV Pharmaceuticals, Inc. is a precision oncology company, which is engaged in the discovery and development of small molecule, tumor-agnostic therapies targeting p53.
The Company’s lead product candidate, PC14586, is an orally available small molecule designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild type p53. PC14586 is designed to restore the wild-type conformation by occupying the crevice created by the tyrosine to cysteine mutation in amino acid position 220.
The Company is also using its precision oncology platform to develop a pipeline of oral small molecule product candidates, which structurally correct other p53 hotspot mutations to restore their wild-type function and product candidates that target certain cancers where wild-type p53 function is silenced.